ClinicalTrials.gg
RecruitingNCT03717844Updated Nov 20, 2025

Registry for Adults With Plasma Cell Disorders (PCD's)

An observational study in Multiple Myeloma, Amyloidosis and Cryoglobulinemia, sponsored by UNC Lineberger Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Primary conditionLeukemia, Plasma CellRegistry: Multiple MyelomaReclassifiedWhy we changed it
Registry
Multiple Myeloma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Plasma Cell
Why
  1. The study's listed conditions name Leukemia, Plasma Cell, a narrower term within Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by UNC Lineberger Comprehensive Cancer Center · Observational

How we know

From the registry’s dates

  • Started Feb 2018; still recruiting 8 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Leukemia, Plasma Cell with a site in United States — 8 open to participants now, 10 under way, none of them phase 3. Leukemia, Plasma Cell · United States.

Started
2018
with 3 others
Observational
2 of 31
2 open now
Registered
24th of 31
by date

Among the 31 studies in Leukemia, Plasma Cell with a site in United States, this one is one of 4 that started in 2018, is one of 2 observational ones, and was the 24th registered.

Leukemia, Plasma Cell

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Open to participants now

8 of the 31 studies in Leukemia, Plasma Cell with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Leukemia, Plasma Cell studies recruiting now, 12 (41%) set no upper age limit and 13 (45%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Leukemia, Plasma Cell with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).

Read the detailed description

OBJECTIVES:

Primary

  1. To create a Registry (to be called the PCD Registry) of PCD patients
  2. To have participating patients complete an assessment at enrollment and to repeat the assessment longitudinally over time.

Secondary

  1. To gather information, including patterns of patient care, that would lend support for future research in the PCD population. Specific research questions would be explored within separate IRB-reviewed protocols.
  2. To bank blood samples for future research involving adults with PCD's, specifically examining p16INK4a and other markers to be specified in future, separate, IRB-approved protocols as specific research questions are identified.

OUTLINE: Patients complete an assessment at baseline and then longitudinally over time which involves a multi-dimensional inter-disciplinary evaluation of a patient's functional status (ability to live independently at home and in the community), co-morbid medical conditions, cognition, psychological status, social functioning and support, medication review, and nutritional status. Patients' medical records are also reviewed.

03

Conditions studied

  • Multiple Myeloma
  • Amyloidosis
  • Cryoglobulinemia
  • Castleman's Disease
  • Light Chain Deposition Disease
  • Heavy Chain Deposition Disease
  • Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes
  • Smoldering Multiple Myeloma
  • Plasma Cell Leukemia
04

In context

Leukemia, Plasma Cell Reclassified

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Lead sponsor

UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 431 studies on the registry; 96 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Compared within Leukemia, Plasma Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Myeloma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients have a documented diagnosis of PCD defined as the presence of a monoclonal protein and/or monoclonal plasma cell population.

Examples of PCDs include but are not limited to monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple (active) myeloma; plasma cell leukemia; Castleman's disease; amyloidosis; light and/or heavy chain deposition disease; Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes (POEMS) syndrome; and cryoglobulinemia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients have an outpatient appointment or are hospitalized inpatient at UNC Cancer Hospitals, or affiliated clinic settings or participating sites for the evaluation and management of a PCD.
  • Patients have a documented diagnosis of PCD defined as the presence of a monoclonal protein and/or monoclonal plasma cell population. Examples of PCDs include but are not limited to monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple (active) myeloma; plasma cell leukemia; Castleman's disease; amyloidosis; light and/or heavy chain deposition disease; Polyneuropathy, Organomegaly, Endocrinopathy,Monoclonal gammopathy and Skin changes (POEMS) syndrome; and cryoglobulinemia.
  • Age ≥18 years.
  • Must consent to participation in this study and agree to complete the assessment at baseline and follow-up time points.
  • Must be able to read and speak English.

Exclusion criteria

Exclusion Criteria:

  • Physical or psychiatric/behavioral illnesses or problems that the treating clinician feels would preclude successful participation in the study.
  • There are no imaging or lab studies required to determine eligibility.
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
07

What researchers measure

Primary outcomes

  1. Creation of a Registry of Plasma Cell Disorder (PCD) patients

    Time frame: 10 years

  2. Completion of baseline and longitudinal assessments in PCD patients

    Time frame: 10 years

Secondary outcomes

  1. Creation of information that would lend support for future PCD research

    Including patterns of patient care that would lend support for future research in patients with confirmed PCD's.

    Time frame: 10 years

  2. Response rates of assessment in PCD patients and their satisfaction with the assessment

    Done by measuring: * percentage of patients contacted who consent to complete the assessment percentage of patients able to complete the self-administered portion of the assessment without assistance * the length of time necessary to complete the assessment * the variance and number of missing items * the percentage of geriatric assessments that contain all three of the following items: Timed Up and Go Assessment, Blessed Orientation-Memor Concentration Test, and the healthcare professional-rated Karnofsky performance status.

    Time frame: 10 years

08

Study locations

1 of 1 sites recruiting
  • North Carolina Cancer Hospital
    Chapel Hill, North Carolina 27599, United States
    Recruiting
    • Sascha Tuchman, MD · Principal investigator
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2018 (actual). Primary completion is estimated for Feb 2028, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2018
First posted
Oct 24, 2018
StartActual
Feb 9, 2018
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2029
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03717844
Responsible party
Sponsor
First posted
Oct 24, 2018
Start date
Feb 9, 2018
Primary completion
Feb 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Nov 20, 2025

Study contacts

Nicholas Mangieri
Contact
nicholas_mangieri@med.unc.edu
(919) 966-4432
Kendall Conder
Contact
kendall_conder@med.unc.edu
(919) 966-4432
Sascha Tuchman, MD
principal investigator · UNC Lineberger Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion